ClinicalTrials.Veeva

Menu

A Study of Oral Contraception Under Simulated OTC Conditions (OPTION)

H

HRA Pharma

Status and phase

Terminated
Phase 3

Conditions

Contraception

Treatments

Drug: Norgestrel 0.075 mg tablets

Study type

Interventional

Funder types

Industry

Identifiers

NCT03559010
151042-001

Details and patient eligibility

About

This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.

Full description

Subjects will be primarily recruited via passive recruiting methods, such as in-store posters, direct mail postcards, and digital space advertising.

Respondents to advertisements will either call Clinical Research Organization (CRO) call center or visit the study website for initial screening (during which data regarding age, gender, and minimal study exclusion criteria will be collected) and scheduling of an in-person enrollment visit at a local participating research site.

During the face-to-face enrollment visit, potential subjects who meet the inclusion and exclusion criteria for the study will be given an (empty) study medication package and will be allowed as much time as they need to review the information on the outside of the entire package. Subjects will then be asked if the product is OK or not OK for them to use.

Qualified subjects then will be allowed to purchase (pharmacy sites) or be given (clinic sites) the study product.

Approximately 47 sites will be used, comprising retail pharmacy research sites and women's health clinics or adolescents' clinics.

Enrollment

189 patients

Sex

Female

Ages

12+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

-Women who are willing purchase (in the pharmacies) or be provided (in the clinics) oral contraception for their own use for the purposes of the study

Exclusion criteria

  • Cannot read, speak and understand English
  • Cannot see well enough to read information on the label

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

189 participants in 1 patient group

Use Phase Norgestrel 0.075 mg
Experimental group
Description:
Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
Treatment:
Drug: Norgestrel 0.075 mg tablets

Trial documents
2

Trial contacts and locations

44

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems